Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder
IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Urovant Sciences (Nasdaq: UROV) announced today that it has submitted a New Drug Application (NDA)…